The effects of combined treatment of losartan and ramipril on hypertension and related complications

다국어 초록 (Multilingual Abstract)

Purpose Polypharmacy has been an important strategy for the management of hypertension. The aim of this study was to investigate the effect of combined treatment of losartan with ramipril on hypertension, myocardial infarction and vascular remodeling in disease animal models.
Methods In 8-telemetered spontaneous hypertensive rats (SHRs) orally treated with various doses of drugs or vehicle by cross-over protocol, systolic blood pressure (SBP), mean arterial pressure (MAP) and heart rate (HR) were measured. The infarct size was measured in rats subjected to 30 min occlusion of the left anterior descending coronary artery (LAD) followed by 150 min reperfusion in myocardial ischemia/reperfusion (MI/R) rats injected drugs or vehicle once through femoral vein 15 min before inducing ischemia. The neointima formation and DNA synthesis in intima and media layer of the blood vessels were measured in cuff-induced vascular injury mice orally treated with drugs for 2 weeks.
Results As compared with single treatment, the combination therapy of both drugs significantly decreased SBP and MAP without significant reflex tachycardia. The combined treatment of both drugs significantly increased the expression of endothelial nitric oxide synthase (eNOS) in coronary arterial tissues including area at occlusion. The combination therapy significantly decreased the thickness of vascular media layer and the number of bromodeoxyuridine (BrdU)-positive cells in both intima and media.
Conclusion The present data suggest that the combination therapy with fixed doses of losartan and ramipril may exert greater BP-lowering effects with protection against myocardial infarction and vascular remodeling.

참고문헌 (Reference)

1 Wynne BM, "Vascular smooth muscle cell signaling mechanisms for contraction to angiotensin II and endothelin-1" 3 : 84-95, 2009

2 Arauz-Pacheco C, "Treatment of hypertension in adults with diabetes" 26 (26): S80-S82, 2003

3 Alexander RW, "Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective" 25 : 155-161, 1995

4 Messerli FH, "The transition from hypertension to heart failure : contemporary update" 5 : 543-551, 2017

5 Kockx MM, "The endothelium during cuff-induced neointima formation in the rabbit carotid artery" 13 : 1874-1884, 1993

6 ONTARGET Investigators, "Telmisartan, ramipril, or both in patients at high risk for vascular events" 358 (358): 1547-1559, 2008

7 de Leeuw PW, "Short-and long-term effects of ramipril in hypertension" 59 : 79D-82D, 1987

8 Ruggenenti P, "Role of remission clinics in the longitudinal treatment of CKD" 19 : 1213-1224, 2008

9 Schoolwerth AC, "Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association" 104 : 1985-1991, 2001

10 Mann SJ, "Redefining β-blocker use in hypertension : selecting the right β-blocker and the right patient" 11 : 54-65, 2017

11 Becker RA, "Ramipril : review of pharmacology" 59 : 3D-11D, 1987

12 Mead TJ, "Proliferation assays(BrdU and EdU)on skeletal tissue sections" 1130 : 233-243, 2014

13 Simon JN, "Nitric oxide synthase regulation of cardiac excitation-contraction coupling in health and disease" 73 : 80-91, 2014

14 Wermelt JA, "Management of arterial hypertension" 42 : 515-526, 2017

15 Crozier I, "Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group" 91 : 691-697, 1995

16 Lee YM, "Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats" 10 : 852-858, 1997

17 Correa F, "Inhibition of the nitric oxide/cyclic guanosine monophosphate pathway limited the cardioprotective effect of post-conditioning in hearts with apical myocardial infarction" 765 : 472-481, 2015

18 Kokubo Y, "Impact of intima-media thickness progression in the common carotid arteries on the risk of incident cardiovascular disease in the Suita study" 7 (7): e007720-, 2018

19 김혜진, "Hypoxic pulmonary vasoconstriction and vascular contractility in monocrotaline-induced pulmonary arterial hypertensive rats" 대한약리학회 20 (20): 641-647, 2016

20 Te Riet L, "Hypertension: renin-angiotensin-aldosterone system alterations" 116 : 960-975, 2015

21 Azar RR, "Global impact of the new European and American hypertension guidelines : a perspective from Lebanon" 21 : 684-686, 2019

22 Chen YJ, "First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension" 11 : CD008170-, 2018

23 Inseon Yi, "Enhanced Effect of Losartan and Rosuvastatin on Neointima Hyperplasia" 대한약학회 33 (33): 593-600, 2010

24 Tedesco MA, "Effects of losartan on hypertension and left ventricular mass: a long-term study" 12 : 505-510, 1998

25 Chaudhary K, "Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?" 11 (11): 375-381, 2009

26 Gentile G, "Dual renin-angiotensin system blockade for nephroprotection : still under scrutiny" 129 (129): 39-41, 2015

27 Mann JF, "Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial" 31 (31): 414-421, 2013

28 이정진, "Drug Synergism of Antihypertensive Action in Combination of Telmisartan with Lercanidipine in Spontaneous Hypertensive Rats" 대한약학회 33 (33): 1411-1418, 2010

29 Roush GC, "Diuretics for hypertension : A review and update" 29 : 1130-1137, 2016

30 McComb MN, "Direct vasodilators and sympatholytic agents" 21 : 3-19, 2016

31 Park ES, "Cordycepin, 3’-deoxyadenosine, prevents rat hearts from ischemic/reperfusion injury via activation of Akt/GSK-3β/p70S6K signaling pathway and HO-1 expression" 14 : 1-9, 2014

32 Avdeev SN, "Combination therapy is a new standard for treatment of pulmonary arterial hypertension" 90 : 72-80, 2018

33 Guerrero-Garcia C, "Combination therapy in the treatment of hypertension" 7 : 212531-, 2018

34 Gradman AH, "Combination therapy in hypertension" 13 : 146-154, 2011

35 Cappella P, "Cell proliferation method : click chemistry based on BrdU coupling for multiplex antibody staining" 72 : 1-17, 2015

36 Lin Y, "Blood pressure lowering effect of calcium channel blockers on perioperative hypertension : a systematic review and meta-analysis" 97 : e13152-, 2018

37 Bath PM, "Blood pressure in acute stroke : to treat or not to treat : that is still the question" 49 : 1784-1790, 2018

38 Heeneman S, "Angiotensin-converting enzyme and vascular remodeling" 101 : 441-454, 2007

39 Hill RD, "Angiotensin II receptor blockers(ARB, ARb)" StatPearls 2019

40 Daemen MJ, "Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall" 68 : 450-456, 1991

41 Montezano AC, "Angiotensin II and vascular injury" 16 : 431-, 2014

42 Parish RC, "Adverse effects of angiotensin converting enzyme(ACE)inhibitors. An update" 7 : 14-31, 1992

43 Overlack A, "ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management" 15 : 72-78, 1996

44 Nair AB, "A simple practice guide for dose conversion between animals and human" 7 (7): 27-31, 2016

45 Pongsuthana S, "A comparison of the efficacy and renal side effects of antihypertensive drugs “angiotensin receptor blockers” (ARBs) in Rajavithi hospital" 99 (99): S56-S92, 2016